Brief: Following Pre-NDA Meeting With The FDA, Urogen Announces Rolling NDA Submission For Ugn-102 To Begin January 2024
03/10/2023 13:37
Oct 3 (Reuters) - Urogen Pharma Ltd UR8.F :
* FOLLOWING PRE-NDA MEETING WITH THE FDA, UROGEN ANNOUNCES
ROLLING
NDA SUBMISSION FOR UGN-102 TO BEGIN JANUARY 2024
Source text for Eikon: ID:nBw9lNfHKa
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors